Trials / Conditions / ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
3 registered clinical trials studyying ROS1-positive Non-Small Cell Lung Cancer (NSCLC).
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Unknown | Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) NCT03972189 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Available | Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid NCT06797362 | Nuvalent Inc. | — |
| No Longer Available | Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC NCT06841874 | Nuvation Bio Inc. | — |